Plasma cell isolation

Unleash the power of innovation

CD138+ Plasma Cell Isolation Redefined

The expression of CD138, a marker expressed on the surface of plasma cells, plays a critical role in the identification of plasma cell tumors and multiple myeloma cells.1 While the characteristics of plasma cells can vary depending on the disease stage and biological traits of the patient, studies have proven the prognostic value of specific antigen expression patterns in neoplastic plasma cells.2

Traditionally, the assessment of plasma cells in bone marrow involves a time-consuming and labor-intensive method involving ficoll density gradient separation, which results in the loss of antigens, including CD138, from the plasma cell surface, necessitating immediate staining and analysis.2 MARS® platform incorporates their proprietary in-flow immuno-magnetic separation technology to efficiently isolate CD138+ plasma cells directly from unprocessed bone marrow samples. This innovative approach simplifies the isolation process, enabling fast and dependable analysis of CD138 expression in plasma cells.

The efficient isolation of CD138+ plasma cells can be pivotal for various clinical and therapeutic research applications. This includes developing new tools for in diagnosing, prognosing and treatment of multiple myeloma, eg. with FISH or Next-Generation Sequencing. In autoimmune diseases, CD138+ plasma cells are investigated due to their role in producing autoantibodies. They are also of interest in vaccine, immunity, immunodeficiency disorders or bone marrow transplantation research and development.

1. Chilosi M, Adami F, Lestani M, et al. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Mod Pathol. 1999;12(12): 1101-1106.

2. Kumar S, Kimlinger T, Morice W. Immunophenotyping in multiple myeloma and related plasma cell disorders. Best Pract Res Clin Haematol. 2010 Sep;23(3):433-51.

MARS® platform: Transforming Challenges into Solutions

The MARS® platform utilizes an exceptional in-flow technology that eliminates the need for columns. This feature offers flexibility in optimizing workflows to achieve the highest possible purity and recovery rates. Furthermore, the absence of a matrix allows users to directly isolate target cells (even at low percentages) from unprocessed samples, such as peripheral blood, bone marrow, and cord blood.

Blood test icon


automatic 2x or 3x separation guarantees unmatched consistency and a seamless user experience

Cell icon


far superior to conventional methods, our technology ensures high cell purity and recovery that consistently outperforms

Blood Test icon


reusable and cleanable fluidics reduces the cost, while pre-set cleaning protocols offer unprecedented efficiency

CD138+ Cell Isolation 

Directly from Bone Marrow

CD138 expression is important in diagnosing plasma cell tumors and multiple myeloma. This application note highlights the MARS® platform as an innovative tool for efficiently isolating CD138+ plasma cells from bone marrow samples. This streamlined approach facilitates rapid and reliable isolation of plasma cells, revolutionizing the research for plasma cell-related disorders.

Application note highlighting CD138+ Plasma Cell Enrichment directly from Bone Marrow with MARS platform

Download brochure

Case study: CD138 Plasma Cell Enrichment for FISH

Setting New Benchmarks with the MARS® Platform

The MARS® platform offers advanced cell isolation capabilities, surpassing traditional cell isolation methods for FISH assays, consistently meeting the enrichment benchmarks. As we gear up to release the latest detailed case study, discover how MARS® isolated cells can improve FISH tests outcome for the accurate detection of multiple myeloma.

Easy, sequential purification process

The MARS® platform simplifies the cell isolation process through its fast and easy workflow, which improves purity while maintaining high recovery of cells. Our instrument uses an automated one- to three-pass cell enrichment process and involves minimal hands-on time.

 Other unique features include matrix-free cell isolation, economical consumables, and sterilizable and reusable fluidics. The obtained samples can also be rapidly re-run through the magnetic channel to maximize efficiency.

Explore other MARS® Platform Applications

Cell Therapy

MARS® Bar platform supports your cell development process from end to end, from small-scale optimization, through easy upscaling, to cell manufacturing.

Learn More

Explore other MARS® Platform Applications

tumor cell

Stem cell isolation

The MARS® platform uses an efficient method, eliminating the need for red blood cell (RBC) lysis and density gradient centrifugation, while yielding high purity samples.

Learn More

 Contact us and Redefine Your Cell Isolation Workflow!